This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Healthcare Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use.
It's no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in the United States, with few products launched relative to those approved, low uptake of the products that are available, and formulary restrictions that sometimes favor branded biologics over biosimilar options. But given the benefits that biosimilars can provide, some physicians are taking matters into their own hands with concerted efforts to bring these products to the clinic. This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Healthcare Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use.
Read more about the value-based pathway here, and find the Articularis Rheumatology Network here.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.